Evidence map›Paper›PMID 37260078›Full record

ArticleNucleic acids research2023

DIANA-miRPath v4.0: expanding target-based miRNA functional analysis in cell-type and tissue contexts.

Spyros Tastsoglou, Giorgos Skoufos, Marios Miliotis, Dimitra Karagkouni, Ioannis Koutsoukos, Anna Karavangeli, Filippos S Kardaras, Artemis G Hatzigeorgiou

Abstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Folinic Acid Improves Healing of Diabetic Foot Ulcers.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Time- and dose-dependent regulation of circular RNAs in the response of triple-negative breast cancer cells to ionizing radiation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Spyros TastsoglouDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.
Giorgos SkoufosDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.
Marios MiliotisDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.
Dimitra KaragkouniDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Ioannis KoutsoukosDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.
Anna KaravangeliDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.
Filippos S KardarasDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.
Artemis G HatzigeorgiouDIANA-Lab, Department of Computer Science and Biomedical Informatics, Univ. of Thessaly, Lamia 35131, Greece.ORCID 0000-0003-1414-5668

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DIANA-miRPath is an online miRNA analysis platform harnessing predicted or experimentally supported miRNA interactions towards the exploration of combined miRNA effects. In its latest version (v4.0, http://www.microrna.gr/miRPathv4), DIANA-miRPath breaks new ground by introducing the capacity to tailor its target-based miRNA functional analysis engine to specific biological and/or experimental contexts. Via a redesigned modular interface with rich interaction, annotation and parameterization options, users can now perform enrichment analysis on Gene Ontology (GO) terms, KEGG and REACTOME pathways, sets from Molecular Signatures Database (MSigDB) and PFAM. Included miRNA interaction sets are derived from state-of-the-art resources of experimentally supported (DIANA-TarBase v8.0, miRTarBase and microCLIP cell-type-specific interactions) or from in silico miRNA-target interactions (updated DIANA-microT-CDS and TargetScan predictions). Bulk and single-cell expression datasets from The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression project (GTEx) and adult/fetal single-cell atlases are integrated and can be used to assess the expression of enriched term components across a wide range of states. A discrete module enabling enrichment analyses using CRISPR knock-out screen datasets enables the detection of selected miRNAs with potentially crucial roles within conditions under study. Notably, the option to upload custom interaction, term, expression and screen sets further expands the versatility of miRPath webserver.

Indexed as

MicroRNAsSoftwareCell CommunicationDatabases, ChemicalMicroRNAs

Identifiers

PMID37260078
PMCPMC10320185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.